Jaknat Tofacitinib 5 Mg Tablets

About Jaknat Tofacitinib 5 Mg Tablets

Jaknat Tofacitinib 5 mg Tablets is a medication that contains tofacitinib, a Janus kinase (JAK) inhibitor used primarily for treating autoimmune diseases.

Tofacitinib works by targeting and inhibiting specific enzymes (JAK1, JAK2, JAK3) involved in the inflammatory process. By blocking these enzymes, it helps to reduce the activity of the immune system that can cause inflammation in conditions like rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis.

Indications

• Rheumatoid Arthritis: Tofacitinib is used to treat moderate to severe rheumatoid arthritis in adults who have not responded adequately to methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs).
• Psoriatic Arthritis: It can be used to treat psoriatic arthritis, especially when other treatments haven't worked.
• Ulcerative Colitis: Tofacitinib is approved for the treatment of moderate to severe ulcerative colitis in adults who have not responded to or cannot tolerate other therapies.

Dosage and Administration

• Dosage: The typical starting dose is 5 mg twice daily for adults, depending on the specific condition being treated and individual patient response. In some cases, the dose may be adjusted.
• Administration: It is taken orally, with or without food. Tablets should be swallowed whole.

Side Effects

Common side effects of Tofacitinib include:

• Upper respiratory tract infections
• Headache
• Diarrhea
• High blood pressure
• Nasopharyngitis (inflammation of the nose and throat)

Serious side effects can occur, including:

• Increased risk of infections (due to immune suppression)
• Blood clots (especially in the lungs or deep veins)
• Liver issues (monitoring is recommended)
• Cancer risk: Some studies suggest a potential increased risk of certain cancers, so regular monitoring is important.

Precautions and Warnings

• Infection risk: Tofacitinib may increase the risk of serious infections, including tuberculosis, fungal infections, and bacterial infections. Vaccinations should be updated before starting treatment.
• Liver function: Regular blood tests to monitor liver function are important.
• Blood cell counts: It can affect red blood cells, white blood cells, and platelets, so regular blood monitoring is required.

It is important to discuss any medical conditions (like liver or kidney disease, or a history of infections) and current medications with your healthcare provider before starting Jaknat (Tofacitinib).

Important Considerations

• People with a history of tuberculosis or other infections, or those who are immunocompromised, should be cautious about using this drug.
• Tofacitinib may interact with other medications, so your doctor should be aware of any other treatments you're undergoing.

Always follow the exact instructions from your healthcare provider to ensure the best possible outcome with this medication.